News | Artificial Intelligence | October 26, 2022

Industry life sciences veteran to advance growth strategy and execution

Jieun Choe, chief marketing officer, Viz.ai. Source: Viz.ai

Jieun Choe, chief marketing officer, Viz.ai. Source: Viz.ai 

 


October 26, 2022 —  Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, has named life sciences veteran Jieun Choe as chief marketing officer (CMO). Choe will report to CEO Chris Mansi, overseeing global marketing strategy, brand and communications, product marketing and demand generation. 

“Jieun’s deep experience and proven track record in driving growth with expert execution will be invaluable as we continue to expand our footprint worldwide,” said CEO Chris Mansi, M.D. “The addition of her customer-centric approach and strategic, growth mindset to our c-suite will help propel Viz.ai into new frontiers.” 

Choe was most recently chief strategy and marketing officer at Certara, a global leader in biosimulation, where she headed the global marketing team and drove the strategic planning process. Choe was also instrumental in helping lead the company to a successful IPO in December 2020. Earlier in her career, she worked in product management and strategy at Guidant and Boston Scientific, leading cross-functional teams and driving product strategy and launches. 

“I am thrilled to join Viz.ai as it embarks on its next stage of growth,” said Choe. “The company’s purpose-driven, diverse culture is impressive, empowering the Viz team to innovate outstanding solutions to improve patient outcomes and increase access to life-saving care. I look forward to working with the team to accelerate the momentum and fuel growth.” 

Choe received her Bachelors of Arts in Public Policy and Economics from Stanford University and a Masters of Business Administration from Stanford University’s Graduate School of Business

For more information: www.viz.ai 

Find more RSNA22 coverage here


Related Content

News | Radiation Oncology

May 10, 2024 — Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical ...

Time May 10, 2024
arrow
News | ARRS

May 8, 2024 — Compared to males, women in radiology are at a consistently higher risk of not matching into diagnostic ...

Time May 08, 2024
arrow
News | Contrast Media

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
News | ARRS

May 7, 2024 — The American Roentgen Ray Society (ARRS) announced that Philip Costello, MD, the 118th ARRS President and ...

Time May 07, 2024
arrow
News | Radiology Business

May 6, 2024 — ScreenPoint Medical’s Board of Directors has announced the appointment of Peter Kroese as the new Chief ...

Time May 06, 2024
arrow
News | Mammography

May 6, 2024 — Enable Me, a VELA Medical company, cited major new research by Siemens Healthineers entitled, “The future ...

Time May 06, 2024
arrow
Feature | Digital Radiography (DR) | By Melinda Taschetta-Millane

Digital radiography (DR) continues to advance at a rapid pace with today’s technological innovations and evolving ...

Time May 06, 2024
arrow
News | Radiology Business

May 2, 2024 — GE HealthCare has announced a new radiation therapy computed tomography (CT) solution with innovative ...

Time May 02, 2024
arrow
Feature | Radiology Business

Beginning this spring, ITN will begin sending out a bi-monthly survey to our readers on a variety of topics, which we ...

Time May 02, 2024
arrow
Feature | Radiology Business | By William T. Thorwarth Jr., MD, FACR

As we witness a mounting backlash against prior authorization in healthcare, we must explore more effective alternatives ...

Time May 02, 2024
arrow
Subscribe Now